Ares Capital Corp (ARCC) · Oct 27, 2026 · Acquisition
$2.6B acquisition — $10.88 per MFIC share vs. $12.86 preliminary NAV
Ares Capital’s acquisition of MFIC adds scale at a price below MFIC’s preliminary NAV, but earnings accretion remains unquantified until closing.
Ares Capital is already the largest publicly traded BDC and is using scale to expand its U.S. middle-market direct-lending platform, while MFIC enters the deal after portfolio marks pressured its 2026 net asset value.
This is a meaningful consolidation, not a routine disclosure. Ares Capital is acquiring MFIC for approximately $2.6 billion in total enterprise value, with closing targeted for the first half of 2027. The transaction adds another public BDC platform and borrower portfolio to ARCC, but it does not immediately change earnings because the deal still requires MFIC stockholder and regulatory approval.
| Deal term | Filing figure |
|---|---|
| Total enterprise value | ~$2.6 billion |
| Total consideration per MFIC share | $10.88 |
| Cash consideration | ~$1.21 per share |
| Ares Capital stock consideration | ~$9.67 per share |
| MFIC preliminary NAV per share | ~$12.86 |
| Premium to MFIC closing price | ~30.1% |
| Maximum Ares Capital shares issued | ~41 million |
| Expected post-closing ownership | ARCC holders ~95%; MFIC holders ~5% |
The headline economics favor ARCC if MFIC’s NAV estimate holds. The $10.88 consideration is roughly 15% below MFIC’s preliminary $12.86 NAV, giving ARCC an apparent purchase discount rather than paying a premium to book value. But that NAV is unaudited, management-prepared, and subject to change when MFIC reports its final September 30 figures on November 5. 〔0〕
The target’s recent operating backdrop makes the discount strategically useful. MFIC’s June 2026 quarter produced a $17.5 million decrease in net assets from operations, including a $49.8 million net change in unrealized losses, while six-month net assets from operations declined by $44.4 million. That suggests ARCC is buying a pressured portfolio at a valuation that could leave room for accretion, rather than acquiring a rapidly compounding platform at a premium.
The benefit is plausible, but not yet proven in numbers. Management says the transaction should be accretive to core earnings and support future dividends, but the filing gives no quantified pro forma earnings increase, cost savings, or dividend uplift. The consideration is also predominantly stock, and ARCC may issue up to approximately 41 million shares, so the eventual economics depend on the special dividend, ARCC’s NAV, and its share price at closing. 〔1〕
Bottom line: This advances ARCC’s scale strategy on apparently favorable purchase terms, especially if MFIC’s preliminary NAV survives the final report. The deal is meaningfully positive for the business story, but the promised earnings accretion remains a closing-dependent claim rather than a demonstrated result.
MFIC Q3 results, November 5, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!